이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biogen 관리

관리 기준 확인 4/4

Biogen's CEO는 Chris Viehbacher, Nov2022 에 임명되었습니다 의 임기는 1.58 년입니다. 총 연간 보상은 $ 4.07M, 39.3% 로 구성됩니다. 39.3% 급여 및 60.7% 보너스(회사 주식 및 옵션 포함). 는 $ 1.57M 가치에 해당하는 회사 주식의 0.005% 직접 소유합니다. 1.57M. 경영진과 이사회의 평균 재임 기간은 각각 4.1 년과 5 년입니다.

주요 정보

Chris Viehbacher

최고 경영자

US$4.1m

총 보상

CEO 급여 비율	39.3%
CEO 임기	1.6yrs
CEO 소유권	0.005%
경영진 평균 재임 기간	4.1yrs
이사회 평균 재임 기간	5yrs

최근 관리 업데이트

Recent updates

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Jun 28

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Apr 14

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Mar 27

CEO 보상 분석

Chris Viehbacher 의 보수는 Biogen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$4m	US$2m	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$30m	US$154k	US$3b

보상 대 시장: Chris 의 총 보상 ($USD 4.07M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 13.50M ).

보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chris Viehbacher (63 yo)

1.6yrs

테뉴어

US$4,069,913

보상

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christopher Viehbacher	President	1.6yrs	US$4.07m	0.0048% $ 1.6m
Michael McDonnell	Executive VP & CFO	3.8yrs	US$7.17m	0.013% $ 4.5m
Nicole Murphy	Head of Pharmaceutical Operations & Technology	2.4yrs	US$5.71m	0.0066% $ 2.2m
Susan Alexander	Executive VP & Chief Legal Officer	18.4yrs	US$6.70m	0.035% $ 12.0m
Rachid Izzar	Head of Global Product Strategy & Commercialization	3.4yrs	US$5.45m	0.0067% $ 2.2m
Robin Kramer	Senior VP & Chief Accounting Officer	5.6yrs	데이터 없음	0.0043% $ 1.4m
Charles Triano	Senior VP & Head of Investor Relations	1.3yrs	데이터 없음	데이터 없음
Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	4.4yrs	데이터 없음	데이터 없음
Adam Keeney	Executive VP & Head of Corporate Development	1.2yrs	데이터 없음	0.00045% $ 151.9k
Ginger Gregory	Executive VP & Chief Human Resources Officer	6.9yrs	US$5.08m	0.0093% $ 3.1m
Alisha Alaimo	President & Head of North America	6.9yrs	데이터 없음	데이터 없음
Anabella Villalobos	Head of Biotherapeutics & Medicinal Sciences	6.9yrs	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: BIIB 의 관리팀은 경험 ( 4.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Viehbacher	President	1.6yrs	US$4.07m	0.0048% $ 1.6m
Stephen Sherwin	Independent Director	14.3yrs	US$435.32k	0.013% $ 4.3m
William Hawkins	Independent Director	5yrs	US$425.73k	0.0045% $ 1.5m
Caroline Dorsa	Independent Chair of the Board	14.4yrs	US$646.13k	0.017% $ 5.8m
Eric Rowinsky	Independent Director	14.3yrs	US$418.02k	0.014% $ 4.8m
Maria Freire	Independent Director	3yrs	US$412.90k	0.0031% $ 1.0m
Monish Patolawala	Independent Director	less than a year	데이터 없음	0.00092% $ 310.5k
Jesus Mantas	Independent Director	5yrs	US$433.23k	0.0051% $ 1.7m
Susan Langer	Independent Director	less than a year	US$334.53k	0.0019% $ 637.9k

5.0yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: BIIB 의 이사회는 경험(평균 재직 기간 5 년)으로 간주됩니다.

Biogen 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Pomerantz LLP Announces Filing of a Class Action against Biogen Inc

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Consensus EPS estimates fall by 11%

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Full year 2023 earnings: EPS misses analyst expectations

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 11%

Biotech And Pharma Diversification Pays Off

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 23%

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Now 22% undervalued

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Now 20% undervalued

Insider recently sold US$804k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$259k worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Executive VP exercised options and sold US$415k worth of stock

CEO 보상 분석